[1]
|
Soreide, J.A. (2019) Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives. Therapeutics and Clinical Risk Management, 15, 1469-1477. https://doi.org/10.2147/TCRM.S204303
|
[2]
|
Lin, C.Y., Yeh, H.C., Hsu, C.M., et al. (2015) Clinicopathologial Features of Gastric Hepatoid Adenocarcinoma. Biomedical Journal, 38, 65-69. https://doi.org/10.4103/2319-4170.126860
|
[3]
|
Baek, S.K., Han, S.W., Oh, D.Y., et al. (2011) Clinicopath-ologic Characteristics and Treatment Outcomes of Hepatoid Adenocarcinoma of the Stomach, a Rare but Unique Subtype of Gastric Cancer. BMC Gastroenterology, 11, Article No. 56. https://doi.org/10.1186/1471-230X-11-56
|
[4]
|
Nishida, K., Toji, T., Taniguchi, K., et al. (2023) High-Grade En-dometrial Carcinoma with a Hepatoid Carcinoma-Like Component. International Journal of Gynecological Pathology, 42, 63-67.
https://doi.org/10.1097/PGP.0000000000000852
|
[5]
|
Li, M., Fan, Y. and Lu, H. (2021) Hepatoid Adenocarcino-ma of the Lung. Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177/15330338211057983
|
[6]
|
Yang, C., Sun, L., Lai, J.Z., et al. (2019) Primary Hepatoid Car-cinoma of the Pancreas: A Clinicopathological Study of 3 Cases with Review of Additional 31 Cases in the Literature. International Journal of Surgical Pathology, 27, 28-42.
https://doi.org/10.1177/1066896918783468
|
[7]
|
Acosta, A.M. and Pins, M.R. (2019) Hepatoid Carcinoma of the Ovary: Clinical, Histopathologic, and Immunophenotypic Features. Archives of Pathology & Laboratory Medicine, 143, 883-889.
https://doi.org/10.5858/arpa.2017-0485-RS
|
[8]
|
Devi, N.R., Sathyalakshmi, R., Devi, J., et al. (2015) Hepatoid Adenocarcinoma of the Gall Bladder—A Rare Variant. Journal of Clinical and Diagnostic Research, 9, ED09-ED10. https://doi.org/10.7860/JCDR/2015/10799.6324
|
[9]
|
Nagai, Y., Kato, T., Harano, M., et al. (2014) A Case of AFP-Producing Esophagogastric Junction Cancer with Liver Metastases with a Good Response to Chemotherapy. Gan to Kagaku Ryoho, 41, 2349-2351.
|
[10]
|
Wang, N., Kong, R., Han, W., et al. (2021) Aberrant Beta-Catenin Activity in Hepatoid Adenocarcinoma of the Stomach. Current Molecular Medicine, 21, 655-664. https://doi.org/10.2174/0929867327666200522215607
|
[11]
|
Su, J.S., Chen, Y.T., Wang, R.C., et al. (2013) Clini-copathological Characteristics in the Differential Diagnosis of Hepatoid Adenocarcinoma: A Literature Review. World Journal of Gastroenterology, 19, 321-327.
https://doi.org/10.3748/wjg.v19.i3.321
|
[12]
|
Inagawa, S., Shimazaki, J., Hori, M., et al. (2001) Hepatoid Adenocar-cinoma of the Stomach. Gastric Cancer, 4, 43-52.
https://doi.org/10.1007/s101200100016
|
[13]
|
Xia, R., Zhou, Y., Wang, Y., et al. (2021) Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Frontiers in Oncology, 11, Article ID: 633916. https://doi.org/10.3389/fonc.2021.633916
|
[14]
|
Mckusick, V.A. and Amberger, J.S. (1994) The Morbid Anatomy of the Human Genome: Chromosomal Location of Mutations Causing Disease (Update 1 December 1993). Journal of Medical Genetics, 31, 265-279.
https://doi.org/10.1136/jmg.31.4.265
|
[15]
|
Yoshizawa, J., Ishizone, S., Ikeyama, M., et al. (2017) Gastric Hepatoid Adenocarcinoma Resulting in a Spontaneous Gastric Perforation: A Case Report and Review of the Literature. BMC Cancer, 17, Article No. 368.
https://doi.org/10.1186/s12885-017-3357-7
|
[16]
|
Simmet, V., Noblecourt, M., Lizee, T., et al. (2018) Chemothera-py of Metastatic Hepatoid Adenocarcinoma: Literature Review and Two Case Reports with Cisplatin Etoposide. Oncolo-gy Letters, 15, 48-54.
https://doi.org/10.3892/ol.2017.7263
|
[17]
|
Scott, L.J. (2018) Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs, 78, 747-758.
https://doi.org/10.1007/s40265-018-0903-9
|
[18]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[19]
|
Ganesh, K., Stadler, Z.K., Cercek, A., et al. (2019) Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nature Reviews Gastroenterology & Hepatology, 16, 361-375. https://doi.org/10.1038/s41575-019-0126-x
|
[20]
|
Arakawa, Y., Tamura, M., Aiba, K., et al. (2017) Significant Response to Ramucirumab Monotherapy in Chemotherapy-Resistant Recurrent Alpha-Fetoprotein-Producing Gastric Cancer: A Case Report. Oncology Letters, 14, 3039-3042.
https://doi.org/10.3892/ol.2017.6514
|
[21]
|
Zou, M., Li, Y., Dai, Y., et al. (2019) AFP-Producing Hepatoid Adeno-carcinoma (HAC) of Peritoneum and Omentum: A Case Report and Literature Review. OncoTargets and Therapy, 12, 7649-7654.
https://doi.org/10.2147/OTT.S216501
|
[22]
|
Wang, Y., Sun, L., Li, Z., et al. (2019) Hepatoid Adenocarcinoma of the Stomach: A Unique Subgroup with Distinct Clinicopathological and Molecular Features. Gastric Cancer, 22, 1183-1192.
https://doi.org/10.1007/s10120-019-00965-5
|